

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2802271/jiri-vencovsky-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

284 papers	19,583 citations	56 h-index	138 g-index
387 ext. papers	25,385 ext. citations	3.7 avg, IF	6.77 L-index

#	Paper	IF	Citations
284	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 2569-81		4825
283	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. <i>Scientific Reports</i> , <b>2021</b> , 11, 1	4.9	2785
282	2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1580-8	2.4	2158
281	The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 795-810	2.4	540
280	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1955-1964	2.4	393
279	European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 4-12	2.4	355
278	Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 797-804	2.4	339
277	Autoantibody profiles in the sera of European patients with myositis. <i>Annals of the Rheumatic Diseases</i> , <b>2001</b> , 60, 116-23	2.4	261
276	International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. <i>Rheumatology</i> , <b>2004</b> , 43, 49-54	3.9	249
275	Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 805-11	2.4	241
274	Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. <i>British Journal of Rheumatology</i> , <b>2001</b> , 40, 1262-73		226
273	Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. <i>Annals of the Rheumatic Diseases</i> , <b>2006</b> , 65, 1635-8	2.4	217
272	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 2271-2282	9.5	210
271	Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2003</b> , 62, 427-30	2.4	194
270	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 2582-91		182
269	A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 51-57	2.4	157
268	The role of MRI in the assessment of polymyositis and dermatomyositis. <i>Rheumatology</i> , <b>2007</b> , 46, 1174-9	3.9	149

267	Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. <i>Scandinavian Journal of Rheumatology</i> , <b>2000</b> , 29, 95-102	1.9	142
266	Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1898-904	2.4	140
265	IL-10 gene promoter polymorphisms in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , <b>1998</b> , 27, 142-5	1.9	137
264	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 491-496	2.4	125
263	Prospective new biological therapies for rheumatoid arthritis. <i>Autoimmunity Reviews</i> , <b>2009</b> , 9, 102-7	13.6	107
262	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 30-39	2.4	105
261	Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. <i>Journal of Autoimmunity</i> , <b>2019</b> , 101, 48-55	15.5	96
260	Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. <i>Annals of the Rheumatic Diseases</i> , <b>2006</b> , 65, 242-5	2.4	96
259	Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 3239-47		94
258	A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1020-1030	2.4	91
257	Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 696-701	2.4	90
256	Delays in assessment of patients with rheumatoid arthritis: variations across Europe. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1822-5	2.4	88
255	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1558-66	2.4	85
254	Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1410-1	2.4	78
253	The importance of cell surface RANKL in rheumatoid arthritis. <i>Arthritis Research</i> , <b>2005</b> , 7, P152		78
252	Citrullinated peptide-specific CD19+B cells are present in synovial tissue and peripheral blood of patients with rheumatoid arthritis. <i>Arthritis Research</i> , <b>2005</b> , 7, P149		78
251	Expression of IgVH mRNAs in plasma cells derived from rheumatoid arthritis synovium detected by single-cell RT-PCR. <i>Arthritis Research</i> , <b>2003</b> , 5, 119		78
250	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 983-93	13.6	76

249	Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. <i>Genes and Immunity</i> , <b>2015</b> , 16, 470-80	4.4	75
248	Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 40-48	9.5	75
247	Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 836-43	2.4	75
246	Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 961-5	2.4	75
245	Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. <i>Medicine (United States)</i> , <b>2012</b> , 91, 206-211	1.8	74
244	Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country or wealth?. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 2010-21	2.4	71
243	A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 64-9	2.4	71
242	The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. <i>Annals of the Rheumatic Diseases</i> , <b>2000</b> , 59, 141-2	2.4	71
241	Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> ,	2.4	67
240	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. <i>RMD Open</i> , <b>2017</b> , 3, e000507	5.9	66
239	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> ,	2.4	65
238	Tumour necrosis factor alpha G-->A -238 and G-->A -308 polymorphisms in juvenile idiopathic arthritis. <i>Rheumatology</i> , <b>2002</b> , 41, 223-7	3.9	64
237	Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 55-62	2.4	61
236	A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 49-59	9.5	58
235	Reliability and validity of the myositis disease activity assessment tool. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 3593-9		58
234	Primary Sjögren's syndrome in children and adolescents: proposal for diagnostic criteria. <i>Clinical and Experimental Rheumatology</i> , <b>1999</b> , 17, 381-6	2.2	58
233	Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. <i>Rheumatology</i> , <b>2012</b> , 51, 1226-34	3.9	56
232	Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. <i>Lupus</i> , <b>1998</b> , 7, 29-36	2.6	55

231	Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor $\beta$ Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 679-689	9.5	53
230	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. <i>Neuromuscular Disorders</i> , <b>2020</b> , 30, 70-92	2.9	53
229	Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2011</b> , 13, R122	5.7	52
228	Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 3154-60		50
227	Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 1285-9	2.4	49
226	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 996-1002	2.4	48
225	A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 96-102	2.4	47
224	Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. <i>Rheumatology</i> , <b>2015</b> , 54, 2010-4	3.9	45
223	The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. <i>Rheumatology</i> , <b>2014</b> , 53, 1520-6	3.9	45
222	Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 71-4	2.4	45
221	Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. <i>Clinical and Experimental Rheumatology</i> , <b>2009</b> , 27, 958-63	2.2	45
220	Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 252	5.7	42
219	Higher frequency of allele 2 of the interleukin-1 receptor antagonist gene in patients with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , <b>2001</b> , 44, 2387-91		41
218	52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. <i>Rheumatology</i> , <b>2017</b> , 56, 2093-2101	3.9	40
217	Identification of common epitopes on gliadin, enterocytes, and calreticulin recognised by antigliadin antibodies of patients with coeliac disease. <i>Gut</i> , <b>1999</b> , 44, 168-73	19.2	40
216	Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis. <i>Cytokine</i> , <b>2015</b> , 73, 36-43	4	39
215	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 911-923	9.5	36
214	MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 124	5.7	35

213	Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to anti-TNF (human tumor necrosis factor) biologic therapy: a randomized, controlled trial. <i>2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 898-910</i>	5.7	34
212	Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology, 2017, 69, 898-910</i>	9.5	33
211	The metastasis promoting protein S100A4 is increased in idiopathic inflammatory myopathies. <i>Rheumatology, 2011, 50, 1766-72</i>	3.9	33
210	Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis. <i>Rheumatology, 2009, 48, 1590-4</i>	3.9	32
209	Splicing variant of augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. <i>Annals of the Rheumatic Diseases, 2018, 77, 602-611</i>	2.4	31
208	Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. <i>Rheumatology International, 2013, 33, 259-63</i>	3.6	31
207	OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. <i>Annals of the Rheumatic Diseases, 2015, 74, 2123-9</i>	2.4	30
206	Therapy of myositis: biological and physical. <i>Current Opinion in Rheumatology, 2014, 26, 704-11</i>	5.3	29
205	Increased serum concentration of immune cell derived microparticles in polymyositis/dermatomyositis. <i>Immunology Letters, 2010, 128, 124-30</i>	4.1	28
204	Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. <i>Journal of Clinical Investigation, 2015, 125, 4612-24</i>	15.9	27
203	Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis. <i>PLoS ONE, 2017, 12, e0185323</i>	3.7	25
202	Idiopathic Inflammatory Myopathies. <i>Rheumatic Disease Clinics of North America, 2019, 45, 569-581</i>	2.4	25
201	Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. <i>Cytokine, 2012, 58, 165-8</i>	4	25
200	Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. <i>Arthritis and Rheumatology, 2017, 69, 1090-1099</i>	9.5	24
199	Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis. <i>Arthritis Research and Therapy, 2017, 19, 79</i>	5.7	24
198	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Annals of the Rheumatic Diseases, 2017, 76, 782-791</i>	2.4	24
197	The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. <i>Cytokine, 2011, 55, 116-21</i>	4	24
196	Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis. <i>PLoS ONE, 2015, 10, e0132674</i>	3.7	24



195	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. <i>Rheumatology</i> , <b>2017</b> , 56, 1884-1893	3.9	23
194	Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 740357	4.3	23
193	Physiological evidence for diversification of IFN $\alpha$ and IFN $\gamma$ mediated response programs in different autoimmune diseases. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 49	5.7	21
192	Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1750-2	2.4	21
191	Heterogenous nuclear RNP C1 and C2 core proteins are targets for an autoantibody found in the serum of a patient with systemic sclerosis and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , <b>1997</b> , 40, 2172-7		21
190	Novel adipokine fibroblast growth factor 21 is increased in rheumatoid arthritis. <i>Physiological Research</i> , <b>2012</b> , 61, 489-94	2.1	20
189	Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 245	5.7	19
188	Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, 454	5.7	19
187	Pregnancy outcome in idiopathic inflammatory myopathy patients in a multicenter study. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 2492-4	4.1	19
186	Endogenous HLA-DR-restricted presentation of the cartilage antigens human cartilage gp-39 and melanoma inhibitory activity in the inflamed rheumatoid joint. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 2150-9		19
185	Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0183420	3.7	19
184	Arthritis in idiopathic inflammatory myopathy: clinical features and autoantibody associations. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1133-9	4.1	18
183	Interrater reliability and aspects of validity of the myositis damage index. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1272-6	2.4	18
182	Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies. <i>Scandinavian Journal of Immunology</i> , <b>2016</b> , 84, 100-9	3.4	18
181	Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort. <i>PLoS ONE</i> , <b>2014</b> , 9, e103495	3.7	17
180	Resistin in idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, R111	5.7	17
179	Polymorphism in the immunoglobulin VH gene V1-69 affects susceptibility to rheumatoid arthritis in subjects lacking the HLA-DRB1 shared epitope. <i>British Journal of Rheumatology</i> , <b>2002</b> , 41, 401-10		16
178	No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. <i>Clinical Rheumatology</i> , <b>2012</b> , 31, 67-71	3.9	15

177	MRI scoring methods used in evaluation of muscle involvement in patients with idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , <b>2017</b> , 29, 623-631	5.3	15
176	Heterogeneity of disease phenotype in monozygotic twins concordant for rheumatoid arthritis. <i>Rheumatology</i> , <b>1995</b> , 34, 215-20	3.9	15
175	Expression and Regulation of PIWIL-Proteins and PIWI-Interacting RNAs in Rheumatoid Arthritis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0166920	3.7	15
174	Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. <i>Rheumatology International</i> , <b>2019</b> , 39, 469-478	3.6	15
173	Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 111-7	2.2	15
172	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. <i>Rheumatology</i> , <b>2015</b> , 54, 2273-82	3.9	14
171	The role of resistin in inflammatory myopathies. <i>Current Rheumatology Reports</i> , <b>2013</b> , 15, 336	4.9	14
170	Decrease in serum interleukin-21 levels is associated with disease activity improvement in patients with recent-onset rheumatoid arthritis. <i>Physiological Research</i> , <b>2014</b> , 63, 475-81	2.1	14
169	The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102797	13.6	14
168	The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region. <i>RMD Open</i> , <b>2015</b> , 1, e000044	5.9	13
167	The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels. <i>Cytokine</i> , <b>2013</b> , 64, 441-7	4	13
166	The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, 468	5.7	13
165	International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, R2	5.7	13
164	Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2055-2062	3.9	12
163	Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1 positive polymyositis and dermatomyositis. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 158	5.7	12
162	Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 341	5.7	12
161	Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain. <i>BMC Musculoskeletal Disorders</i> , <b>2018</b> , 19, 264	2.8	12
160	Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis. <i>Cytokine</i> , <b>2019</b> , 116, 13-20	4	11



159	Serum levels of interferon $\beta$ do not correlate with disease activity in patients with dermatomyositis/polymyositis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 879-80	2.4	11
158	Rheumatoid arthritis: the goal rather than the health-care provider is key. <i>Lancet, The</i> , <b>2006</b> , 367, 450-2	4.0	11
157	Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. <i>Rheumatology</i> , <b>2020</b> , 59, 1026-1030	3.9	11
156	THU0150 Long-Term Safety and Efficacy of SB4 (Etanercept Biosimilar) in Patients with Rheumatoid Arthritis: Comparison between Continuing SB4 and Switching from Etanercept Reference Product To SB4. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 236.1-236	2.4	11
155	Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients. <i>Rheumatology and Therapy</i> , <b>2017</b> , 4, 57-69	4.4	10
154	Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1- $\beta$ autoantibodies in adult patients with myositis. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 117	5.7	10
153	Interleukin-20 is triggered by TLR ligands and associates with disease activity in patients with rheumatoid arthritis. <i>Cytokine</i> , <b>2017</b> , 97, 187-192	4	10
152	Advanced glycation end-product pentosidine is not a relevant marker of disease activity in patients with rheumatoid arthritis. <i>Physiological Research</i> , <b>2007</b> , 56, 771-777	2.1	10
151	Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment. <i>Clinical and Experimental Rheumatology</i> , <b>2007</b> , 25, 540-5	2.2	10
150	High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort. <i>Biomarkers</i> , <b>2015</b> , 20, 47-51	2.6	9
149	Alterations in activin A-myostatin-follistatin system associate with disease activity in inflammatory myopathies. <i>Rheumatology</i> , <b>2020</b> , 59, 2491-2501	3.9	9
148	Polymorphism of the extrapituitary prolactin promoter and systemic sclerosis. <i>Rheumatology International</i> , <b>2010</b> , 30, 1691-3	3.6	9
147	The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis. <i>Clinical and Experimental Rheumatology</i> , <b>2004</b> , 22, 395-402	2.2	9
146	Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci et al. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, e40	2.4	8
145	Adipokine profile is modulated in subcutaneous adipose tissue by TNF $\alpha$ inhibitors in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 2054-6	2.4	8
144	Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. <i>PLoS ONE</i> , <b>2016</b> , 11, e0165498	3.7	8
143	Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, e65	2.4	8
142	The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial. <i>Journal of the American Society of Hypertension</i> , <b>2014</b> , 8, 780-90		7

141	CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis. <i>Clinical Immunology</i> , <b>2010</b> , 136, 139-47	9	7
140	Monozygotic rheumatoid arthritis twin pairs express similar levels of conserved immunoglobulin V gene in polyclonal rheumatoid factors irrespective of disease status. <i>Scandinavian Journal of Immunology</i> , <b>1995</b> , 42, 147-57	3.4	7
139	Idiopathic inflammatory myopathies. <i>Nature Reviews Disease Primers</i> , <b>2021</b> , 7, 86	51.1	7
138	Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 342-343	2.2	7
137	Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 495-499	2.4	6
136	Clinical trials roundup in idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , <b>2011</b> , 23, 605-11	5.3	6
135	Treatment-resistant inflammatory myopathy. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2010</b> , 24, 427-40	5.3	6
134	Response to: Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration by Marshall et al. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, e38	2.4	6
133	Immunological investigation in children with juvenile chronic arthritis. <i>Medical Science Monitor</i> , <b>2001</b> , 7, 99-104	3.2	6
132	Response to: Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required by Moots et al. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, e25	2.4	5
131	Inflammatory myopathy associated with statins: report of three cases. <i>Modern Rheumatology</i> , <b>2014</b> , 24, 366-71	3.3	5
130	Pentosidine, an advanced glycation end-product, may reflect clinical and morphological features of hand osteoarthritis. <i>Open Rheumatology Journal</i> , <b>2012</b> , 6, 64-9	0.2	5
129	International collaboration including patients is essential to develop new therapies for patients with myositis. <i>Current Opinion in Rheumatology</i> , <b>2017</b> , 29, 234-240	5.3	4
128	Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study. <i>Rheumatology International</i> , <b>2019</b> , 39, 1037-1043	3.6	4
127	Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 156	5.7	4
126	Cytokines and inflammatory mediators as promising markers of polymyositis/dermatomyositis. <i>Current Opinion in Rheumatology</i> , <b>2020</b> , 32, 534-541	5.3	4
125	Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 11	5.7	4
124	Patients with Rheumatoid Arthritis Acquire Sustainable Skills for Home Monitoring: A Prospective Dual-country Cohort Study (ELECTOR Clinical Trial I). <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 658-667	4.1	3

123	FRI0186 Long-term safety and efficacy of 4-weekly certolizumab pegol monotherapy and combination therapy in rheumatoid arthritis: 5-year results from an open-label extension study. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A435.1-A435	2.4	3
122	Clinical associations of IgG antibodies to the ribonucleoprotein p67 polypeptide in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>1992</b> , 51, 1313-7	2.4	3
121	Clinical-morphological correlation of polymyositis and dermatomyositis. <i>Scandinavian Journal of Rheumatology</i> , <b>1987</b> , 67, 32-5	1.9	3
120	Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 183-192	5.4	3
119	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1423-1431	2.4	3
118	S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils. <i>Scientific Reports</i> , <b>2021</b> , 11, 6063	4.9	3
117	Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response. <i>Scientific Reports</i> , <b>2021</b> , 11, 11525	4.9	3
116	The role of imaging in evaluating patients with idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 114, 74-81	2.2	3
115	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1472-1479	2.4	2
114	OP0289 A Prospective, Randomized, Open-Label, Assessor-Blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids versus Glucocorticoids Alone in Patients with Polymyositis and Dermatomyositis (Prometheus Trial). <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 171.1-171	2.4	2
113	SAT0436 Abatacept in the Treatment of Adult Dermatomyositis and Polymyositis: Artemis, a Randomized, Treatment Delayed-Start Trial. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 817.3-818	2.4	2
112	FRI0128 A Phase III Randomised, Double-Blind Clinical Study Comparing SB4, An Etanercept Biosimilar, With Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-Week Results). <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 147.3-147	2.4	2
111	SAT0250 A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective and Less Costly Than Standard Dosing in Patients with Ankylosing Spondylitis Over Two Years: A Propensity Score-Matched Cohort Study. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 749.2-749	2.4	2
110	A7.11 Genetic Variation in Promoter Sequence of B-Cell-Activating Factor of the TNF Family (BAFF) in Patients with Idiopathic Inflammatory Myopathies (IIM). <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A51.3-A52	2.4	2
109	Somatic mutation and CDR3 length of immunoglobulin lambda variable region genes in the synovium of patients with rheumatoid arthritis. <i>Annals of the New York Academy of Sciences</i> , <b>1997</b> , 815, 319-23	6.5	2
108	Therapeutic strategies in polymyositis and dermatomyositis. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2004</b> , 1, 369-374		2
107	Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis. <i>Biomolecules</i> , <b>2020</b> , 11,	5.9	2
106	How Imaging Can Assist with Diagnosis and Monitoring of Disease in Myositis. <i>Current Rheumatology Reports</i> , <b>2020</b> , 22, 62	4.9	2

105	The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 173	5.7	2
104	SAT0146 Earth Explorer 2, A Phase IIB Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and The Tumor Necrosis Factor Antagonist Golimumab in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 75, 717.2-718	2.4	2
103	Arthritis in Idiopathic Inflammatory Myopathies. <i>Current Rheumatology Reports</i> , <b>2019</b> , 21, 70	4.9	2
102	Altered dynamics of lipid metabolism in muscle cells from patients with idiopathic inflammatory myopathy is ameliorated by 6 months of training. <i>Journal of Physiology</i> , <b>2021</b> , 599, 207-229	3.9	2
101	Polymyositis: does it really exist as a distinct clinical subset?. <i>Current Opinion in Rheumatology</i> , <b>2021</b> , 33, 537-543	5.3	2
100	Plasma heat shock protein 90 levels in patients with spondyloarthritis and their relation to structural changes: a cross-sectional study. <i>Biomarkers in Medicine</i> , <b>2021</b> , 15, 5-13	2.3	2
99	Response to: Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria by Cavagna. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, e51	2.4	1
98	A6.26 Analysis of circulating mirnas in patients with axial spondyloarthritis with different spinal involvement. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, A66.1-A66	2.4	1
97	A3.10 Plasma levels of heat shock protein 90 correlate with disease activity, lung involvement and skin fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, A35.1-A35	2.4	1
96	THU0127 Development of Draft Criteria for Arthralgia that is Clinically Suspect for Progression to Rheumatoid Arthritis; Results of Phase 1. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 240.1-240	2.4	1
95	SAT0151 Long-term safety of 4-weekly certolizumab pegol in rheumatoid arthritis: 5 year results from an open label extension study. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 523.1-523	2.4	1
94	THU0528 Decrease in Circulating Visfatin Levels is Associated with Disease Activity Improvement in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 366.1-366	2.4	1
93	A1.48 Enhanced expression of CD11c on non-classical CD16+ peripheral blood monocytes in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A20.2-A21	2.4	1
92	SAT0349 A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective, but Substantially Less Costly than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Matched Observational Study. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 719.1-719	2.4	1
91	FRI0543 Pregnancy Outcome in Adult Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 583.2-583	2.4	1
90	A3.30 Plasma level of HSP70 protein is increased in czech patients with idiopathic inflammatory myopathy. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A54.1-A54	2.4	1
89	A10.3 Arthritis in Patients with Idiopathic Inflammatory Myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A72.2-A72	2.4	1
88	SAT0188 Clinical and Ultrasonographic Characteristics of Arthritis in Patients with Idiopathic Inflammatory Myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A644.3-A645	2.4	1

87	A7.24 The Pentanucleotide Insertion in HSPA1B Gene is Associated with Idiopathic Inflammatory Myopathy. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A56.2-A56	2.4	1
86	THU0253 ANTI-PM-SCL autoantibodies in polymyositis and dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 240.2-240	2.4	1
85	Myositis associated autoantibodies detected using a novel recombinant protein blotting: clinical associations. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, A9-A10	2.4	1
84	Immunoglobulin variable region (IgV) gene expression in rheumatoid factors from monozygotic twins with rheumatoid arthritis. <i>Annals of the New York Academy of Sciences</i> , <b>1997</b> , 815, 324-6	6.5	1
83	Quantiferon-TB Gold test in screening for latent tuberculosis before and during antitumour necrosis factor treatment. <i>Arthritis Research and Therapy</i> , <b>2007</b> , 9, P33	5.7	1
82	SAT0324 SEXUAL HEALTH IN WOMEN AND MEN WITH SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1107.2-1108	2.4	1
81	Clinical Features of Myositis: Muscular Manifestations <b>2020</b> , 37-46		1
80	The expression profile of miR-23b is not altered in peripheral blood mononuclear cells of patients with idiopathic inflammatory myopathies. <i>F1000Research</i> , <b>2013</b> , 2, 223	3.6	1
79	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	1
78	FRI0216 Long-Term Safety and Efficacy of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 510.1-510	2.4	1
77	Response to: Lower anti-drug antibodies with etanercept biosimilar: Can Ctrough explain the differences? By Shah. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, e61	2.4	1
76	The dysregulation of monocyte subpopulations in individuals at risk of developing rheumatoid arthritis. <i>Rheumatology</i> , <b>2021</b> , 60, 1823-1831	3.9	1
75	Interleukin-35 in idiopathic inflammatory myopathies. <i>Cytokine</i> , <b>2021</b> , 137, 155350	4	1
74	High miR-451 expression in peripheral blood mononuclear cells from subjects at risk of developing rheumatoid arthritis. <i>Scientific Reports</i> , <b>2021</b> , 11, 4719	4.9	1
73	Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 222-9	2.2	1
72	S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 338-339	2.2	1
71	Cigarette smoking and clinical response to certolizumab pegol treatment in Hungarian, Czech, and Slovak patients with rheumatoid arthritis: 104-week data from the CIMDORA prospective, non-interventional study. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 1010-1018	2.2	1
70	Clusterin is upregulated in serum and muscle tissue in idiopathic inflammatory myopathies and associates with clinical disease activity and cytokine profile. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 1021-1032	2.2	1



69	S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity. <i>BMC Rheumatology</i> , <b>2020</b> , 4, 13	2.9	o
68	Hsp90 Levels in Idiopathic Inflammatory Myopathies and Their Association With Muscle Involvement and Disease Activity: A Cross-Sectional and Longitudinal Study.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 811045	8.4	o
67	Elevated Tenascin-C Serum Levels in Patients With Axial Spondyloarthritis. <i>Physiological Research</i> , <b>2020</b> , 69, 653-660	2.1	o
66	IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 745523	8.4	o
65	Idiopathic inflammatory myopathies. <i>Vnitřní Lekarství</i> , <b>2018</b> , 64, 155-163	0.3	o
64	AB1233 GENDER DIFFERENCE IN DISEASE SEVERITY AND TREATMENT OUTCOMES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS (RA), AXIAL SPONDYLOARTHRITIS (AXSPA) AND PSORIATIC ARTHRITIS (PSA) STARTING TREATMENT WITH TARGETED THERAPY IN THE CZECH REPUBLIC. <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> , 75, 1007.1-1008	2.4	o
63	Circulating miR-145 as a marker of therapeutic response to anti-TNF therapy in patients with ankylosing spondylitis. <i>Physiological Research</i> , <b>2021</b> , 70, 255-264	2.1	o
62	Sexual function in patients with idiopathic inflammatory myopathies: a cross-sectional study. <i>Rheumatology</i> , <b>2021</b> , 60, 5060-5072	3.9	o
61	Effect of CTLA4-Ig (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis. <i>Scandinavian Journal of Immunology</i> , <b>2019</b> , 89, e12732	3.4	o
60	The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry.. <i>Rheumatology International</i> , <b>2022</b> , 42, 803	3.6	o
59	Dr. Vencovsky et al reply. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1061	4.1	
58	A3.10 Serum calprotectin is elevated in patients with early rheumatoid arthritis but not in patients at risk of developing rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A36.1-A36	2.4	
57	Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , <b>2020</b> , 49, 361-370	1.9	
56	A6.12 Physiological evidence for diversification of IFN $\gamma$ and IFN $\beta$ mediated response programs in different autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A52.1-A52	2.4	
55	A9.04 SNPS in the baf gene are associated with increased risk of anti-jo-1-positivity and high serum baf levels in patients with myositis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A71.2-A72	2.4	
54	A10.17 Interleukin-20 serum levels correlate with disease activity in rheumatoid arthritis patients and decrease in response to rituximab treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A79.2-A79	2.4	
53	SAT0068 Circulating MIR-126 Is A Marker of Disease Activity in Patients with Early RA but Does Not Differentiate Patients at Risk of Developing RA. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 689.2-689	2.4	
52	A8.06 MicroRNA-125b expression in PBMCs is inversely associated with disease activity in patients with early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A67.1-A67	2.4	



- 51 AB0599 Interleukin-35 in Idiopathic Inflammatory Myopathies. *Annals of the Rheumatic Diseases*, **2016**, 75, 1109.2-1109 2.4
- 50 OP0235 Genetic Risk Factors in Idiopathic Inflammatory Myopathies Are Shared with Other Autoimmune Disorders in European Populations. *Annals of the Rheumatic Diseases*, **2014**, 73, 151.1-151 2.4
- 49 FRI0520 Association Study of the BAFF Genetic Variations in Two Independent Cohorts with Idiopathic Inflammatory Myopathies. *Annals of the Rheumatic Diseases*, **2014**, 73, 575.3-576 2.4
- 48 AB0009 Association of MHC Haplotypes with Idiopathic Inflammatory Myopathy in Cohort of Czech Patients. *Annals of the Rheumatic Diseases*, **2014**, 73, 806.3-806 2.4
- 47 AB0163 Comprehensive Analysis of Circulating Mirnas in Patients with Axial Spondyloarthritis. *Annals of the Rheumatic Diseases*, **2014**, 73, 856.4-857 2.4
- 46 SAT0565 The Expression and Regulation of the Argonaute Protein Family Member PIWIL4 in RA. *Annals of the Rheumatic Diseases*, **2014**, 73, 795.1-795 2.4
- 45 A3.29 Micro-RNA molecules are clearly involved in pathogenesis of idiopathic inflammatory myopathy. *Annals of the Rheumatic Diseases*, **2014**, 73, A53.3-A54 2.4
- 44 OP0034 Efficacy and Safety of Mavrilimumab, A Fully Human GM-CSF-Alpha Monoclonal Antibody in Patients with Rheumatoid Arthritis: Primary Results from the Earth Explorer 1 Study. *Annals of the Rheumatic Diseases*, **2015**, 74, 78.1-78 2.4
- 43 THU0056 Expression of Piwi-interacting RNA in Rheumatoid Arthritis. *Annals of the Rheumatic Diseases*, **2015**, 74, 212.2-212 2.4
- 42 A2.33 Haplotype TTTT in the BAFF gene is associated with idiopathic inflammatory myopathies in HLA-DRB1\*03 negative patients. *Annals of the Rheumatic Diseases*, **2015**, 74, A29.2-A29 2.4
- 41 SAT0189 Rapid Onset of Clinical Benefit in Patients with RA Treated with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GM-CSF-ALPHA: Subanalysis of the Phase IIB Earth Explorer 1 Study. *Annals of the Rheumatic Diseases*, **2015**, 74, 723.3-724 2.4
- 40 FRI0435 Interleukin-35 is Overexpressed in Systemic Sclerosis and its Serum Levels are Elevated in Early Disease. *Annals of the Rheumatic Diseases*, **2015**, 74, 584.3-585 2.4
- 39 SAT0456 Heat Shock Protein 90 Plasma Levels Correlate with Disease Activity, Lung Involvement and Skin Fibrosis in Systemic Sclerosis. *Annals of the Rheumatic Diseases*, **2015**, 74, 825.3-826 2.4
- 38 FRI0592 Serum Calprotectin is Associated with Ultrasound-Determined Active Synovitis in Patients with Rheumatoid Arthritis. *Annals of the Rheumatic Diseases*, **2015**, 74, 642.2-642 2.4
- 37 AB0075 Calcizzarin (S100A11) is Up-Regulated in Rheumatoid Arthritis. *Annals of the Rheumatic Diseases*, **2014**, 73, 829.1-829 2.4
- 36 A7.7 Different Genetic Background of Dermatomyositis and Polymyositis in a Single Centre Cohort. *Annals of the Rheumatic Diseases*, **2013**, 72, A50.2-A50 2.4
- 35 THU0232 Pregnancy outcome in idiopathic inflammatory myopathy patients in a multicenter study. *Annals of the Rheumatic Diseases*, **2013**, 71, 233.3-234 2.4
- 34 SAT0001 IFN signature is associated with autoantibody profiles in patients with myositis. *Annals of the Rheumatic Diseases*, **2013**, 71, 471.1-471 2.4

- 33 SAT0023 Investigation of idiopathic inflammatory myopathy for shared genetic risk factors with other autoimmune disorders: Results of UK myonet. *Annals of the Rheumatic Diseases*, **2013**, 71, 478.3-479.4
- 32 SAT0031 Anti-RO52 autoantibody epitope mapping in european cohort of myositis patients. *Annals of the Rheumatic Diseases*, **2013**, 71, 481.2-481 2.4
- 31 SAT0105 Circulating MIR-223 is downregulated in SERA of patients with early RA after treatment with methotrexate. *Annals of the Rheumatic Diseases*, **2013**, 71, 506.1-506 2.4
- 30 A4.15 Serum Levels of Visfatin and B-Cell Activating Factor of the TNF Family Correlate with Disease Activity in Patients with Myositis. *Annals of the Rheumatic Diseases*, **2013**, 72, A29.2-A29 2.4
- 29 A7.3 Association of Circulating miR-223 and miR-16 with Disease Activity in Patients with Early Rheumatoid Arthritis. *Annals of the Rheumatic Diseases*, **2013**, 72, A48.3-A49 2.4
- 28 FRI0077 Levels of mir-16 in serum associate with response to therapy in patients with early rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2013**, 72, A395.1-A395 2.4
- 27 Genetic variation in promoter sequence of B cell-activating factor gene is associated with increased risk of myositis development. *Annals of the Rheumatic Diseases*, **2010**, 69, A31-A31 2.4
- 26 Metastasis-Promoting protein S100A4 (MTS1) upregulates production of proinflammatory cytokines via TLR-4. *Annals of the Rheumatic Diseases*, **2010**, 69, A38-A39 2.4
- 25 The expression regulation of the HSPA1B gene in patients with myositis is not dependent on the presence of HLA-DRB1\*03 risk allele. *Annals of the Rheumatic Diseases*, **2011**, 70, A19-A20 2.4
- 24 Modulation of subcutaneous adipose tissue adipokines by TNF- $\alpha$  blockade therapy in patients with inflammatory arthritides. *Annals of the Rheumatic Diseases*, **2011**, 70, A85-A85 2.4
- 23 Potential role of S100A4 in an immune response of rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2011**, 70, A85-A85 2.4
- 22 Serum levels of IFN- $\gamma$  do not correlate with disease activity in patients with dermatomyositis/polymyositis. *Annals of the Rheumatic Diseases*, **2011**, 70, A89-A90 2.4
- 21 Inflammatory myopathy associated with statins: report of three cases. *Modern Rheumatology*, **2012**, 1 3.3
- 20 Anti-Ro52 epitope mapping in inflammatory myopathies. *Annals of the Rheumatic Diseases*, **2012**, 71, A50.1-A50 2.4
- 19 IFN signature is associated with autoantibody profiles in patients with myositis. *Annals of the Rheumatic Diseases*, **2012**, 71, A49.1-A49 2.4
- 18 FRI0041 ULTRASOUND-DETECTED SYNOVITIS AMONG INDIVIDUALS AT RISK OF RHEUMATOID ARTHRITIS INCREASES THE RISK OF DEVELOPING CLINICAL ARTHRITIS. *Annals of the Rheumatic Diseases*, **2020**, 79, 595-596 2.4
- 17 THU0365 INCREASED HSP90 IN MUSCLE TISSUE AND PLASMA ASSOCIATES WITH DISEASE ACTIVITY AND SKELETAL MUSCLE INVOLVEMENT IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. *Annals of the Rheumatic Diseases*, **2020**, 79, 414.1-414 2.4
- 16 FRI0002 S100A11 (CALGIZZARIN) IS RELEASED DURING NEUTROPHIL EXTRACELLULAR TRAPS FORMATION AND STIMULATES RELEASE OF IL-6 AND TNF IN RHEUMATOID ARTHRITIS. *Annals of the Rheumatic Diseases*, **2020**, 79, 572.3-572 2.4

15	FRI0255 BODY COMPOSITION IN SCLERODERMA PATIENTS IS ASSOCIATED WITH DISEASE ACTIVITY, SERUM LEVELS OF INFLAMMATORY CYTOKINES AND PARAMETERS OF NUTRITION AND LIPID METABOLISM. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 711.3-712	2.4
14	OP0135 INHIBITION OF HSP90 REDUCES PROGRESSION OF DERMAL FIBROSIS AND INDUCES REGRESSION OF ESTABLISHED EXPERIMENTAL DERMAL FIBROSIS INDUCED BY BLEOMYCIN. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 87-88	2.4
13	SAT0627-HPR SEXUAL QUALITY OF LIFE IN 39 FEMALE PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1273.2-1274	2.4
12	AB0001 PLASMA miRNA PROFILE IN PATIENTS WITH HAND OSTEOARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1305.1-1305	2.4
11	OP0136 THE INFLUENCE OF LONG-TERM EXERCISE AND IN VITRO EXERCISE-MIMICKING STIMULATION ON THE PRODUCTION OF MYOKINES AND CYTOKINES IN MYOTUBES OF PATIENTS WITH CHRONIC IDIOPATHIC INFLAMMATORY MYOPATHIES. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 88.2-88	2.4
10	OP0138 CLUSTERIN ASSOCIATES WITH DISEASE MECHANISMS AND INFLAMMATION IN MYOSITIS PATIENTS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 89.2-89	2.4
9	THU0358 NEGATIVE CHANGES OF BODY COMPOSITION IN MYOSITIS PATIENTS AND THEIR ASSOCIATION WITH DISEASE SPECIFIC CHARACTERISTICS, PHYSICAL ACTIVITY AND NUTRITIONAL STATUS.. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 410.3-410	2.4
8	FRI0262 INCREASED PLASMA LEVELS OF HSP90 ARE ASSOCIATED WITH MORE SEVERE LUNG AND SKIN INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 715-716	2.4
7	SAT0240 Snps in The Baff Gene Are Associated with Increased Risk of Anti-Jo-1-Positivity and High Serum BAFF Levels in Patients with Myositis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 755.2-755	2.4
6	Clinical Trials in Myositis: Where Do We Stand?. <i>Current Treatment Options in Rheumatology</i> , <b>2021</b> , 7, 222-242	1.3
5	AB0952 Serum Visfatin and Resistin, but Not Adiponectin or Leptin, Are Associated with Ultrasound Synovitis in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1227.1-1227	2.4
4	A9.02 Heat shock protein 90 plasma levels correlate with disease activity, skeletal muscle, lung and heart involvement in idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A70.2-A71	2.4
3	Idiopathic inflammatory myopathies - new advances. <i>Neurologie Pro Praxi</i> , <b>2021</b> , 21, 477-484	0.2
2	MyomiRs in cultured muscle cells from patients with idiopathic inflammatory myopathy are modulated by disease but not by 6-month exercise training. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> , 40, 346-357	2.2
1	MyomiRs in cultured muscle cells from patients with idiopathic inflammatory myopathy are modulated by disease but not by 6-month exercise training.. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> , 40, 346-357	2.2